Keros Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Keros Therapeutics, Inc. (KROS) reported Revenue from Contract with Customer, Excluding Assessed Tax of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-03
- Keros Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Keros Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $367.00K, a 99.83% decline year-over-year.
- Keros Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $385.00K, a 87.34% decline year-over-year.
- Keros Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $14.26M, a 3575.77% increase year-over-year.
- Keros Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $244.06M, a 6774.96% increase from fiscal 2024.
- Keros Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $3.55M, a 2250.99% increase from fiscal 2023.
- Keros Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $151.00K.
- Keros Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-03 | $367.00K 10-Q · filed 2026-08-03 | $752.00K derived: sum of 3 quarters · filed 2026-08-03 | $15.01M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $367.00K 10-Q · filed 2026-05-14 | $752.00K derived: sum of 2 quarters · filed 2026-05-14 | $15.01M derived: sum of 3 quarters · filed 2026-05-14 | $33.18M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $385.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $14.65M derived: sum of 2 quarters · filed 2026-03-04 | $32.81M derived: sum of 3 quarters · filed 2026-08-03 | $244.06M 10-K · filed 2026-03-04 |
| 2025-09-30 | $14.26M 10-Q · filed 2025-11-05 | $32.43M derived: sum of 2 quarters · filed 2026-08-03 | $243.68M 10-Q · filed 2025-11-05 | $246.72M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $18.17M 10-Q · filed 2026-08-03 | $229.41M 10-Q · filed 2026-08-03 | $232.46M derived: sum of 3 quarters · filed 2026-08-03 | $232.84M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $211.25M 10-Q · filed 2026-05-14 | $214.29M derived: sum of 2 quarters · filed 2026-05-14 | $214.68M derived: sum of 3 quarters · filed 2026-05-14 | $214.71M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $3.43M derived: sum of 2 quarters · filed 2026-03-04 | $3.47M derived: sum of 3 quarters · filed 2026-03-04 | $3.55M 10-K · filed 2026-03-04 |
| 2024-09-30 | $388.00K 10-Q · filed 2025-11-05 | $425.00K derived: sum of 2 quarters · filed 2025-11-05 | $508.00K 10-Q · filed 2025-11-05 | $651.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $37.00K 10-Q · filed 2025-08-06 | $120.00K 10-Q · filed 2025-08-06 | $263.00K derived: sum of 3 quarters · filed 2025-08-06 | $271.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $83.00K 10-Q · filed 2025-05-06 | $226.00K derived: sum of 2 quarters · filed 2025-05-06 | $234.00K derived: sum of 3 quarters · filed 2025-05-06 | $234.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $151.00K derived: sum of 2 quarters · filed 2025-02-26 | $151.00K derived: sum of 3 quarters · filed 2025-02-26 | $151.00K 10-K · filed 2025-02-26 |
| 2023-09-30 | $8.00K 10-Q · filed 2024-11-06 | $8.00K derived: sum of 2 quarters · filed 2024-11-06 | $8.00K 10-Q · filed 2024-11-06 | $8.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-06 | $0.00 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $20.00M derived: sum of 2 quarters · filed 2024-02-28 | $20.10M derived: sum of 3 quarters · filed 2024-02-28 | $20.10M 10-K · filed 2024-02-28 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | $100.00K derived: sum of 2 quarters · filed 2022-11-03 | $100.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $100.00K 10-Q · filed 2022-08-04 | $100.00K 10-Q · filed 2022-08-04 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $0.00 derived: sum of 2 quarters · filed 2022-03-09 | $0.00 derived: sum of 3 quarters · filed 2022-03-09 | $0.00 10-K · filed 2022-03-09 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | $2.50M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | $2.50M derived: sum of 3 quarters · filed 2021-08-05 | $5.00M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-22 | $2.50M derived: sum of 2 quarters · filed 2021-03-25 | $5.00M derived: sum of 3 quarters · filed 2021-03-25 | $7.50M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $5.00M derived: sum of 2 quarters · filed 2021-03-25 | $7.50M derived: sum of 3 quarters · filed 2021-03-25 | $10.00M 10-K · filed 2021-03-25 |
| 2019-09-30 | $2.50M 10-Q · filed 2020-11-10 | $5.00M derived: sum of 2 quarters · filed 2020-11-10 | $7.50M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $2.50M 10-Q · filed 2020-08-13 | $5.00M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $2.50M 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |